JPMorgan Chase & Co. Analysts Give Bayer (BAYN) a €70.00 Price Target
Bayer (FRA:BAYN) has been given a €70.00 ($81.40) target price by equities research analysts at JPMorgan Chase & Co. in a report released on Tuesday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 12.40% from the company’s current price.
BAYN has been the subject of several other reports. Kepler Capital Markets set a €70.00 ($81.40) price target on shares of Bayer and gave the stock a “neutral” rating in a report on Monday, March 25th. UBS Group set a €110.00 ($127.91) price target on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, March 28th. Deutsche Bank set a €70.00 ($81.40) price target on shares of Bayer and gave the stock a “neutral” rating in a report on Monday, April 1st. DZ Bank reiterated a “neutral” rating on shares of Bayer in a report on Tuesday, April 2nd. Finally, Baader Bank set a €123.00 ($143.02) price target on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company. Bayer presently has an average rating of “Hold” and a consensus price target of €81.80 ($95.12).
FRA BAYN opened at €62.28 ($72.42) on Tuesday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.